Injection Drug Use-Associated Candidemia: Incidence, Clinical Features, and Outcomes, East Tennessee, 2014-2018.

BACKGROUND Injection drug use (IDU) is an established but uncommon risk factor for candidemia. Surveillance for candidemia is conducted in East Tennessee, an area heavily impacted by the opioid crisis and IDU. We evaluated IDU-associated candidemia to characterize the epidemiology and estimate the burden. METHODS We assessed the proportion of candidemia cases related to IDU during January 1, 2014-September 30, 2018, estimated candidemia incidence in the overall population and among persons who inject drugs (PWID), and reviewed medical records to compare clinical features and outcomes among IDU-associated and non-IDU candidemia cases. RESULTS The proportion of IDU-associated candidemia cases in East Tennessee increased from 6.1% in 2014 to 14.5% in 2018. Overall candidemia incidence in East Tennessee was 13.5/100 000, and incidence among PWID was 402-1895/100 000. Injection drug use-associated cases were younger (median age, 34.5 vs 60 years) and more frequently had endocarditis (39% vs 3%). All-cause 30-day mortality was 8% among IDU-associated cases versus 25% among non-IDU cases. CONCLUSIONS A growing proportion of candidemia in East Tennessee is associated with IDU, posing an additional burden from the opioid crisis. The lower mortality among IDU-associated cases likely reflects in part the younger demographic; however, Candida endocarditis seen among approximately 40% underscores the seriousness of the infection and need for prevention.

[1]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[2]  W. Bamberg,et al.  Candida Bloodstream Infections Among Persons Who Inject Drugs — Denver Metropolitan Area, Colorado, 2017–2018 , 2019, MMWR. Morbidity and mortality weekly report.

[3]  G. Allison,et al.  2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  G. Allison,et al.  2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  W. Schaffner,et al.  1722. The Changing Epidemiology of Candidemia in the United States: Injection Drug Use as an Emerging Risk Factor for Candidemia , 2018, Open Forum Infectious Diseases.

[6]  R. Lynfield,et al.  Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals , 2018, The New England journal of medicine.

[7]  C. del Rio,et al.  Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop , 2018, Annals of Internal Medicine.

[8]  W. Schaffner,et al.  Neonatal and Pediatric Candidemia: Results From Population-Based Active Laboratory Surveillance in Four US Locations, 2009–2015 , 2018, Journal of the Pediatric Infectious Diseases Society.

[9]  Jennifer A. Johnson,et al.  Outpatient Parenteral Antimicrobial Therapy Among People Who Inject Drugs: A Review of the Literature , 2018, Open forum infectious diseases.

[10]  W. Schaffner,et al.  Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs — Six Sites, 2005–2016 , 2018, MMWR. Morbidity and mortality weekly report.

[11]  S. Touray,et al.  Reemergence of Intravenous Drug Use as Risk Factor for Candidemia, Massachusetts, USA , 2018, Emerging infectious diseases.

[12]  W. Schaffner,et al.  Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases , 2018, Annals of Internal Medicine.

[13]  Lawrence Scholl,et al.  Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017 , 2018, MMWR. Morbidity and mortality weekly report.

[14]  J. Samet,et al.  Addiction consultation services - Linking hospitalized patients to outpatient addiction treatment. , 2017, Journal of substance abuse treatment.

[15]  S. Yuan.  Fungal Endocarditis , 2016, Brazilian journal of cardiovascular surgery.

[16]  W. Schaffner,et al.  Twenty Years of Active Bacterial Core Surveillance , 2015, Emerging infectious diseases.

[17]  W. Schaffner,et al.  Cultivation of an Adaptive Domestic Network for Surveillance and Evaluation of Emerging Infections , 2015, Emerging infectious diseases.

[18]  A. Lansky,et al.  Population Size Estimates for Men who Have Sex with Men and Persons who Inject Drugs , 2015, Journal of Urban Health.

[19]  L. Harrison,et al.  Declining Incidence of Candidemia and the Shifting Epidemiology of Candida Resistance in Two US Metropolitan Areas, 2008–2013: Results from Population-Based Surveillance , 2015, PloS one.

[20]  R. Weiss,et al.  Initiating buprenorphine treatment for hospitalized patients with opioid dependence: A case series. , 2015, The American journal on addictions.

[21]  B. Kullberg,et al.  Invasive Candidiasis. , 2015, The New England journal of medicine.

[22]  B. Anderson,et al.  Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. , 2014, JAMA internal medicine.

[23]  N. Yapar.  Epidemiology and risk factors for invasive candidiasis , 2014, Therapeutics and clinical risk management.

[24]  J. Nelson,et al.  Use of Opioids or Benzodiazepines and Risk of Pneumonia in Older Adults: A Population‐Based Case–Control Study , 2011, Journal of the American Geriatrics Society.

[25]  C. Viscoli,et al.  Candida Infective Endocarditis: Report of 15 Cases From a Prospective Multicenter Study , 2009, Medicine.

[26]  Jill Manit,et al.  National Survey on Drug Use and Health , 2009 .

[27]  D. Perlman,et al.  Why some injection drug users lick their needles: a preliminary survey. , 2008, The International journal on drug policy.

[28]  D. Levine,et al.  Impact of Empirical-Therapy Selection on Outcomes of Intravenous Drug Users with Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus , 2007, Antimicrobial Agents and Chemotherapy.

[29]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[30]  P. Pappas.  Invasive candidiasis. , 2006, Infectious disease clinics of North America.

[31]  L. Baddour,et al.  Fungal endocarditis, 1995-2000. , 2002, Chest.

[32]  M E Ellis,et al.  Fungal endocarditis: evidence in the world literature, 1965-1995. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  W. Zimmerli,et al.  Incidence and spectrum of severe medical complications among hospitalized HIV-seronegative and HIV-seropositive narcotic drug users , 1996, AIDS.

[34]  J D Sapira,et al.  The Medical Complications of Drug Addiction and the Medical Assessment of the Intravenous Drug User: 25 Years Later , 1993, Annals of Internal Medicine.

[35]  J. Miro,et al.  Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  T. Sorrell,et al.  Disseminated candidiasis: evidence of a distinctive syndrome in heroin abusers. , 1983, British medical journal.

[37]  L. Saravolatz,et al.  Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. , 1982, Annals of internal medicine.

[38]  R. C. Elandt-Johnson,et al.  Rates , 1959, African Studies Bulletin.